Table 5.
CBA for the most extended evaluation of all attributes of the vaccine.
| Cauliflower floret refers to Figure 6 | CBA | Unit cost/QALY | No intervention | Cost A | Intervention | Cost B | NetBenefit (€) | NetBenefit (%) |
|---|---|---|---|---|---|---|---|---|
| Cohort (10,000) | ||||||||
| Cases | 0.40 | 0.100 | ||||||
| 1b | Subject | €7,500 | €82,192 | €29,178 | €53,014 | 3% | ||
| 2b | Caregiver | €1,500 | €16,438 | €5,836 | €10,603 | 1% | ||
| Medical visit | €25 | 0.15 | €37,500 | 0.0225 | €10,088 | €27,413 | 2% | |
| 1b | Subject | €7,500 | €30,822 | €8,291 | €22,531 | 1% | ||
| 2b | Caregiver | €3,750 | €15,411 | €4,146 | €11,265 | 1% | ||
| Hospitalisation | €2,300 | 0.02 | €460,000 | 0.0016 | €96,048 | €363,952 | 23% | |
| 1b | Subject | €25,000 | €13,699 | €2,860 | €10,838 | 1% | ||
| 2b | Caregiver | €10,000 | €5,479 | €1,144 | €4,335 | 0% | ||
| 2c | Non-healthcare cost | €540 | 0.30 | €648,000 | 0.30 | €230,040 | €417,960 | 26% |
| 1c | Vaccine | €141 | 0.86 | €1,213,863 | -€1,213,863 | −75% | ||
| 1b | Death (subject) | €790,000 | 0.000005 | €39,500 | 0.00000025 | €7,229 | €32,272 | 2% |
| 2b | Death (caregiver) | €237,000 | €11,850 | €2,169 | €9,681 | |||
| 3a | QoC | €250,000 | €250,000 | €0 | €250,000 | 16% | ||
| 2a | Indirect effect | Yes | ||||||
| Total | €1,610,891 | €1,610,891 | €0 | −0.6% | ||||
CBA, cost-benefit analysis; QALY, quality-adjusted life-year; QoC, quality of care